RecruitingNCT03349762
Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery
A Real-World Study Investigating Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery
Sponsor
Xi Shan Wang
Enrollment
3,060 participants
Start Date
Nov 2, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of Huaier granules for Prevention of Recurrence and Metastasis of colorectal cancer patients following radical surgery
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Males or females ages 18-75 years;
- The first time to the therapy of patients who received the radical surgery within two months, Postoperative histopathology confirms the diagnosis of colorectal cancer with stage IIB, IIC and III ( TNM classification)
- ECOG score of 0-2;
- No history of malignant tumors;
- The patients are volunteered for the study, sign informed consent form and cooperate with Investigator to collect data.
Exclusion Criteria7
- Patients have basic diseases including heart diseases, cerebrovascular disease, lung disease, severe hypertension or diabetes with poor glycemic control;
- confirmed infections after surgery ;
- Patients who have post-surgery complications or who are currently under the influence of the radical surgery for colorectal cancer;
- Being infected with syphilis or with other blood-borne infectious diseases;
- Pregnancy or lactation; or women of childbearing potential not using contraception;
- Patients who have taken Traditional Chinese Medicines with efficacy and indications similar to that of Huaier granule - including, but not limited to, compound Banmao capsule., Huachansu capsule, Kangai Injection and Pingxiao tablets;
- Patients who are suffering from mental illness or Conditions that are considered not suitable for this study investigators.
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03349762
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations